<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-24233" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Levothyroxine</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Eghtedari</surname>
            <given-names>Bibinaz</given-names>
          </name>
          <aff>University of Arizona</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Correa</surname>
            <given-names>Ricardo</given-names>
          </name>
          <aff>University of Arizona</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Bibinaz Eghtedari declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ricardo Correa declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>28</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-24233.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Oral levothyroxine is primarily indicated for treating primary, secondary, and tertiary hypothyroidism. Primary hypothyroidism is when the problem occurs in the thyroid gland. Secondary hypothyroidism is when the problem is in the pituitary gland, and there is a decrease in the production of thyroid-stimulating hormone (TSH). Tertiary hypothyroidism is sporadic. Additionally, levothyroxine has FDA approval for pituitary thyrotropin suppression as an adjunct to surgery and radioiodine therapy to manage thyrotropin-dependent well-differentiated thyroid cancer. This activity covers important information about prescribing levothyroxine, including mechanism of action, pharmacology, adverse event profiles, eligible patient populations, and monitoring, and highlights the interprofessional team's role in managing various forms of hypothyroidism with levothyroxine.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Explain the mechanism of action of levothyroxine.</p></list-item><list-item><p>Describe the pathophysiology of the three primary forms of hypothyroidism.</p></list-item><list-item><p>Outline the contraindications to initiating therapy with levothyroxine.</p></list-item><list-item><p>Summarize interprofessional team strategies for improving care coordination and communication to advance levothyroxine and improve outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=24233&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=24233">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-24233.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Oral levothyroxine is FDA approved for treating primary, secondary, and tertiary hypothyroidism.<xref ref-type="bibr" rid="article-24233.r1">[1]</xref>&#x000a0;Primary hypothyroidism is due to a problem in the thyroid gland, with the most common cause being an autoimmune condition (Hashimoto thyroiditis) and iatrogenic hypothyroidism (after thyroidectomy). Secondary hypothyroidism is when the problem is in the pituitary gland (from pituitary adenomas to post-surgical intervention), and there is a decrease in thyroid-stimulating hormone(TSH) production. Tertiary hypothyroidism is rare, and the problem is in the hypothalamus with decreased production of a thyroid-releasing hormone(TRH).<xref ref-type="bibr" rid="article-24233.r2">[2]</xref>&#x000a0;</p>
        <p>Additionally, levothyroxine has FDA approval for pituitary thyrotropin suppression as an adjunct to surgery and radioiodine therapy to manage thyrotropin-dependent well-differentiated thyroid cancer.<xref ref-type="bibr" rid="article-24233.r3">[3]</xref>&#x000a0;Injectable levothyroxine is FDA approved for the treatment of myxedema coma or severe hypothyroidism.<xref ref-type="bibr" rid="article-24233.r4">[4]</xref>&#x000a0;</p>
        <p>Off-label usage of levothyroxine includes cadaveric organ recovery and subclinical hypothyroidism.<xref ref-type="bibr" rid="article-24233.r5">[5]</xref><xref ref-type="bibr" rid="article-24233.r6">[6]</xref>&#x000a0;Subclinical hypothyroidism with TSH &#x0003e;10 mIU/L and symptomatic patients should be treated with levothyroxine therapy.<xref ref-type="bibr" rid="article-24233.r7">[7]</xref></p>
      </sec>
      <sec id="article-24233.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Levothyroxine(T4) is a synthetic version of the body&#x02019;s natural thyroid hormone: thyroxine(T4). Normally, the hypothalamus secretes thyrotropin-releasing hormone(TRH), which then stimulates the anterior pituitary to secrete thyroid-stimulating hormone(TSH), which subsequently stimulates the thyroid to secrete 80% thyroxine (T4) and 20% L-triiodothyronine(T3). Fifty percent of thyroxine (T4) then gets converted to its active metabolite L-triiodothyronine (T3). The thyroid hormones then work by binding to thyroid receptor proteins contained within the cell nucleus.<xref ref-type="bibr" rid="article-24233.r8">[8]</xref></p>
        <p>Once inside the nucleus, thyroid hormones directly influence DNA transcription to increase body metabolism by increasing gluconeogenesis, protein synthesis, the mobilization of glycogen stores, and other functions.<xref ref-type="bibr" rid="article-24233.r9">[9]</xref>&#x000a0;In scenarios where this process is interrupted (as seen in primary, secondary, or tertiary hypothyroidism), levothyroxine(LT4) can mimic the body&#x02019;s endogenous T4 production by the thyroid.<xref ref-type="bibr" rid="article-24233.r10">[10]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption: </bold>Orally administered levothyroxine is absorbed from the jejunum and upper ileum (40% to 80%). The relative bioavailability of levothyroxine tablets, compared to an equal dose of oral levothyroxine solution, is approximately 93%. Levothyroxine absorption is increased by fasting and is decreased in the presence of food and malabsorption syndromes. Dietary fiber reduces the bioavailability of T4.</p>
        <p><bold>Distribution: T</bold>hyroid hormones are greater than 99% bound to plasma proteins, including thyroxine-binding globulin (TBG), thyroxine-binding prealbumin (TBPA), and albumin (TBA). T4 has a greater affinity for TBG and TBPA, leading to slower metabolic clearance and a longer half-life of T4 than T3. The free hormone is metabolically active. Many drugs and physiologic conditions alter the binding of thyroid hormones to serum proteins.</p>
        <p><bold>Metabolism: </bold>Thyroid hormones are primarily metabolized by sequential deiodination. Approximately 80% of T3 derives from peripheral T4. The liver is the primary site of degradation for T4 and T3, with T4 deiodination also occurring at several additional sites, including the kidney. T4 is deiodinated to generate an equal quantity of T3 and reverse T3 (rT3). T3 and rT3 are then deiodinated to diiodothyronine. Thyroid hormones are also metabolized via conjugation and undergo enterohepatic recirculation.</p>
        <p><bold>Excretion: </bold>The kidneys primarily excrete thyroid hormones. Approximately 20% of T4 is excreted in the stool. Urinary excretion of T4 decreases with age.</p>
      </sec>
      <sec id="article-24233.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Multiple dosage forms of levothyroxine are available, including oral tablets, capsules, solutions, and parenteral dosage forms. Specific instructions for the dosage forms are as below.</p>
        <list list-type="bullet">
          <list-item>
            <p>Oral: Administer levothyroxine on an empty stomach (acidity increases absorption) at least 30 to 60 minutes before breakfast or 3 to 4 hours after dinner. Do not administer levothyroxine within 4 hours of administration of products that may contain iron or calcium. Do not administer levothyroxine in conjunction with antacids or proton pump inhibitors.<xref ref-type="bibr" rid="article-24233.r11">[11]</xref></p>
          </list-item>
          <list-item>
            <p>Capsule: Swallow whole; Do not crush or cut.</p>
          </list-item>
          <list-item>
            <p>Tablet: May crush into 5 to 10 mL of water and drink immediately. If swallowing the tablet whole, administer with a full glass of water to prevent dysphagia.</p>
          </list-item>
          <list-item>
            <p>Solution: Give either undiluted (directly squeeze contents into the mouth) or diluted in water only (squeeze contents into water, stir, and drink immediately).</p>
          </list-item>
          <list-item>
            <p>Intravenous levothyroxine is exclusively used in the hospital setting, where vital signs can undergo close monitoring.</p>
          </list-item>
          <list-item>
            <p>If the patient can not tolerate anything by mouth, the levothyroxine capsules are used as a suppository and are well absorbed.<xref ref-type="bibr" rid="article-24233.r12">[12]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Adult Dosing</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>For the treatment of hypothyroidism (oral): Adults who are healthy and diagnosed with hypothyroidism for a few months should receive an initial dose of 1.6 mcg/kg/day with a 12.5 to 25 mcg/day dose adjustment every 6 to 8 weeks as needed.</p>
          </list-item>
          <list-item>
            <p>Adults with cardiac disease or elderly over 65 years old and hypothyroidism should receive an initial dose of 25 mcg/day with a dose adjustment of 12.5 to 25 mcg every 4 to 6 weeks as needed.<xref ref-type="bibr" rid="article-24233.r13">[13]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Infant and Pediatric Dosing</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Levothyroxine replacement of 10&#x000a0;to 15 mcg/kg/d should be initiated once newborn screening is positive. Higher doses may be required for infants with severe congenital hypothyroidism. According to product labeling by the FDA following dose of levothyroxine is recommended. The levothyroxine dose is adjusted based on clinical response and laboratory parameters.<xref ref-type="bibr" rid="article-24233.r14">[14]</xref></p>
          </list-item>
          <list-item>
            <p>0&#x000a0;to 3 months:10&#x000a0;to 15 mcg/kg/day</p>
          </list-item>
          <list-item>
            <p>3&#x000a0;to 6 months: 8&#x000a0;to10 mcg/kg/day</p>
          </list-item>
          <list-item>
            <p>6&#x000a0;to 12 months: 6&#x000a0;to&#x000a0; 8 mcg/kg/day</p>
          </list-item>
          <list-item>
            <p>1&#x000a0;to 5 years: 5&#x000a0;to 6 mcg/kg/day</p>
          </list-item>
          <list-item>
            <p>6&#x000a0;to 12 years: 4&#x000a0;to 5 mcg/kg/day</p>
          </list-item>
          <list-item>
            <p>Greater than 12 years but growth and puberty incomplete: 2&#x000a0;to 3 mcg/kg/day</p>
          </list-item>
          <list-item>
            <p>Growth and puberty complete: 1.6 mcg/kg/day</p>
          </list-item>
          <list-item>
            <p>1-year-old children 4&#x000a0;to 6 mcg/kg/d, adolescents 2&#x000a0;to 4 mcg/kg/d, transition to the average adult dose of 1.6 mcg/kg/d once endocrine maturation is complete.</p>
          </list-item>
          <list-item>
            <p>Newborns (0&#x000a0;to 3 months) at risk for cardiac failure: Consider a lower starting dose in newborns at risk for cardiac failure. Based on clinical and laboratory responses, increase the dose every 4 to 6 weeks as needed.&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Myxedema Coma (IV) or Severe Hypothyroidism</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>200 to 400 mcg initial IV loading dose is followed by a daily dose of 1.2 mcg/kg/day, considering lower doses in patients with a history of cardiac disease, arrhythmia, or older patients. Switch to oral therapy (8 mcg/kg/day) when symptoms resolve. The equivalence between intravenous and oral levothyroxine is 0.75 to 1 (for example, 200 mcg IV of levothyroxine equals 266 mcg of oral levothyroxine).<xref ref-type="bibr" rid="article-24233.r15">[15]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Organ Recovery from a Cadaver</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>20 mcg IV bolus to the donor, followed by 10 mcg/hour continuous infusion. Given with methylprednisolone, dextrose, and insulin.<xref ref-type="bibr" rid="article-24233.r16">[16]</xref></p>
          </list-item>
        </list>
        <p><bold>Patients with Hepatic Impairment: </bold>There is no information regarding dosage adjustment of levothyroxine in patients with hepatic impairment in the manufacturer's product labeling.&#x000a0;</p>
        <p><bold>Patients with Renal Impairment:</bold> There is no information regarding dosage adjustment of levothyroxine in patients with renal impairment in the manufacturer's product labeling.</p>
        <p><bold>Pregnancy Considerations:</bold> Pregnancy may increase levothyroxine requirements. Therefore, clinicians should monitor serum TSH levels and adjust levothyroxine dosage during pregnancy.&#x000a0;Pregnant patients with newly diagnosed hypothyroidism should receive initial treatment at 1.8 mcg/kg/day. Adjust the dose every four weeks as needed. If a patient is diagnosed with hypothyroidism before pregnancy, adjust the dose of levothyroxine as needed. After pregnancy, levothyroxine should decrease to 1.6 mcg/kg/day.<xref ref-type="bibr" rid="article-24233.r17">[17]</xref>&#x000a0;The American Thyroid Association (ATA) recommends levothyroxine as the treatment of choice for maternal hypothyroidism. Other thyroid preparations, such as T3 or desiccated preparations, should not be used in pregnancy.<xref ref-type="bibr" rid="article-24233.r18">[18]</xref></p>
        <p><bold>Breastfeeding Considerations:</bold> Levothyroxine (T4) is a component of human milk. Adequate levothyroxine during lactation may normalize milk production in hypothyroid lactating mothers. The health benefits of breastfeeding should be evaluated, along with the mother's clinical requirement for levothyroxine and possible adverse effects on the breastfed infant from levothyroxine. Exogenous replacement of levothyroxine during breastfeeding has no adverse effects in infants. The American Thyroid Association(ATA) suggests hypothyroidism should be treated with levothyroxine in lactating women. After delivery, levothyroxine should be reduced to the patient's preconception dose. Further thyroid function testing should be performed at approximately six weeks postpartum.<xref ref-type="bibr" rid="article-24233.r19">[19]</xref></p>
      </sec>
      <sec id="article-24233.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Generally, adverse events resulting from incorrect dosing (excessive dosing) often form a hyperthyroid-like picture or an allergic reaction to the excipient of the levothyroxine tablets. Levothyroxine 50 mcg tablets don't contain allergic excipients, so there is a decreased risk for immune reactions.<xref ref-type="bibr" rid="article-24233.r20">[20]</xref>&#x000a0;Allergy to the excipients such as dye(tartrazine yellow), lactose, acacia, or even gluten in the levothyroxine tablet may infrequently occur. Hence, allergy or intolerance to levothyroxine can be managed by changing the product, including consideration of gel capsules.<xref ref-type="bibr" rid="article-24233.r15">[15]</xref>Among older persons treated with levothyroxine, levothyroxine at doses more than 75 mcg per day is associated with an increased risk of atrial fibrillation.<xref ref-type="bibr" rid="article-24233.r21">[21]</xref></p>
        <p><bold>Adverse Drug Reactions </bold>(According to System Organ Classification)<xref ref-type="bibr" rid="article-24233.r22">[22]</xref></p>
        <p>
<bold>Cardiovascular Adverse Drug Reactions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Angina pectoris</p>
          </list-item>
          <list-item>
            <p>Tachycardia</p>
          </list-item>
          <list-item>
            <p>Palpitations</p>
          </list-item>
          <list-item>
            <p>Arrhythmia</p>
          </list-item>
          <list-item>
            <p>Myocardial infarction<xref ref-type="bibr" rid="article-24233.r23">[23]</xref></p>
          </list-item>
          <list-item>
            <p>Atrial fibrillation<xref ref-type="bibr" rid="article-24233.r15">[15]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Neuropsychiatric Adverse Drug Reactions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Anxiety</p>
          </list-item>
          <list-item>
            <p>Insomnia(advise the patient to take levothyroxine in the morning)</p>
          </list-item>
        </list>
        <p>
<bold>Gastrointestinal Adverse Drug Reactions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Weight loss</p>
          </list-item>
          <list-item>
            <p>Fatigue</p>
          </list-item>
          <list-item>
            <p>Diarrhea</p>
          </list-item>
          <list-item>
            <p>Emesis</p>
          </list-item>
        </list>
        <p>
<bold>Dermatological Adverse Drug Reactions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Skin rash</p>
          </list-item>
          <list-item>
            <p>Alopecia</p>
          </list-item>
          <list-item>
            <p>Diaphoresis</p>
          </list-item>
        </list>
        <p>
<bold>Endocrine Adverse Drug Reactions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Goiter</p>
          </list-item>
          <list-item>
            <p>Menstrual irregularities</p>
          </list-item>
          <list-item>
            <p>Heat intolerance</p>
          </list-item>
          <list-item>
            <p>Decreased bone mineral density (a result of TSH suppression)<xref ref-type="bibr" rid="article-24233.r13">[13]</xref><xref ref-type="bibr" rid="article-24233.r15">[15]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Hepatic Adverse Drug Reactions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Increased liver enzymes(hepatocellular or mixed pattern)</p>
          </list-item>
          <list-item>
            <p>Immunoallergic hepatitis(with eosinophilia)<xref ref-type="bibr" rid="article-24233.r24">[24]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Drug Interactions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Calcium carbonate, ferrous fumarate, and sevelamer bind to levothyroxine and reduce the absorption of levothyroxine. Administer levothyroxine 4 hours apart from the medications mentioned above. Bile acid sequestrants (e.g., colesevelam, cholestyramine, colestipol) and ion exchange resins, e.g., polystyrene sulfonate, reduce levothyroxine absorption. Administer levothyroxine at least 4 hours before these drugs and monitor TSH levels. Monitor patients treated concomitantly with levothyroxine and&#x000a0;orlistat for changes in thyroid function due to reduced absorption. Gastric acidity is a prerequisite for adequate absorption of levothyroxine. Sucralfate, antacids, and proton pump inhibitors can cause hypochlorhydria and decrease levothyroxine absorption.<xref ref-type="bibr" rid="article-24233.r15">[15]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Furosemide inhibits the protein binding of T4 to thyroid binding globulin(TBG), leading to an increase in free T4; it also competes for T4-binding sites on TBG, so a single high dose of furosemide can acutely lower the total T4 level. Phenytoin and carbamazepine decrease the protein binding of levothyroxine, and total and free T4 may be reduced by 20% to 40%. However, most patients have normal TSH levels and are clinically euthyroid. Therefore, clinicians should closely monitor thyroid hormone parameters. Drugs that increase serum TBG include estrogen, tamoxifen, clofibrate, opioids, mitotane, fluorouracil, and capecitabine.&#x000a0;Estrogen treatment in postmenopausal women is associated with an increase in mean TSH concentration. Rapid estrogen increase is associated with increased TBG and TSH values in treated hypothyroid women. Androgens have the opposite effect and reduce the serum TBG concentrations, thus requiring a decrease in levothyroxine dose. Propranolol and amiodarone, reduce the conversion of T4 to T3. Carbamazepine, phenobarbital, and rifampin induce liver microsomal enzymes, increase levothyroxine metabolism, and decrease serum concentration. Drugs such as dopamine, glucocorticoids, and octreotide can reduce TSH concentration, while lithium, iodine, and sulphonamides interfere with thyroid hormone synthesis.<xref ref-type="bibr" rid="article-24233.r15">[15]</xref><xref ref-type="bibr" rid="article-24233.r25">[25]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Patients treated with immune checkpoint inhibitor therapy (ICPi- pembrolizumab, nivolumab, ipilimumab) may&#x000a0;develop&#x000a0;hypothyroidism due to immune-related adverse events (IRAE), which may require discontinuation of ICPi.<xref ref-type="bibr" rid="article-24233.r26">[26]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>The absorption of levothyroxine can be impaired by soybean, papaya, and grapefruit.<xref ref-type="bibr" rid="article-24233.r25">[25]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-24233.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <list list-type="bullet">
          <list-item>
            <p>Acute myocardial infarction</p>
          </list-item>
          <list-item>
            <p>Uncorrected adrenal insufficiency</p>
          </list-item>
          <list-item>
            <p>Acute myocarditis, pancarditis</p>
          </list-item>
          <list-item>
            <p>Active&#x000a0;cardiac arrhythmias</p>
          </list-item>
          <list-item>
            <p>Thyrotoxicosis</p>
          </list-item>
          <list-item>
            <p>Hyperthyroidism<xref ref-type="bibr" rid="article-24233.r13">[13]</xref><xref ref-type="bibr" rid="article-24233.r15">[15]</xref></p>
          </list-item>
        </list>
        <p><bold>Boxed Warning:&#x000a0;</bold>Levothyroxine or other thyroid hormones, alone or with other therapeutic drugs, should not be used to treat obesity or promote weight loss. In euthyroid patients, levothyroxine dose in the range of daily hormonal requirements is ineffective for weight loss. In addition, larger doses of levothyroxine may lead to serious and life-threatening manifestations, especially when combined with sympathomimetic amines like phentermine used for anorectic effects.</p>
      </sec>
      <sec id="article-24233.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>In adults, monitor TSH levels approximately 6 to 8 weeks after initiating treatment with levothyroxine. Upon achieving the correct dosing of levothyroxine, monitor TSH levels after 4 to 6 months and then every 12 months. Patients should receive education about&#x000a0;the&#x000a0;symptoms of hyperthyroidism and contact their clinician for medication dose&#x000a0;decrease if those symptoms appear.<xref ref-type="bibr" rid="article-24233.r13">[13]</xref><xref ref-type="bibr" rid="article-24233.r15">[15]</xref>&#x000a0;It is&#x000a0;important to consider that TSH is unreliable in patients with secondary or tertiary&#x000a0;hypothyroidism, and the best indicator to adjust dosing will be the free T4 or total T4.<xref ref-type="bibr" rid="article-24233.r27">[27]</xref>&#x000a0;The clinician should counsel the patient to use the same levothyroxine brand because of the narrow therapeutic index.<xref ref-type="bibr" rid="article-24233.r28">[28]</xref></p>
        <p>Oral&#x000a0;semaglutide (GLP-1 analog) increases total T4 exposure when given levothyroxine. In addition, levothyroxine pharmacokinetics is influenced by co-administration with oral semaglutide. Therefore, thyroid function tests should be monitored, and the clinician should adjust the levothyroxine dose.<xref ref-type="bibr" rid="article-24233.r29">[29]</xref></p>
      </sec>
      <sec id="article-24233.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Levothyroxine toxicity is rare; however, it is most likely to occur in the setting of accidental ingestion by children or older adults. Thyroxine (T4) and triiodothyronine (T3) levels rise within 1 to 2 hours of ingestion. In the initial stage of overdose (6 to 12 hours post-ingestion), the common signs of toxicity would be tremulousness, tachycardia, hypertension, anxiety, and diarrhea. Rarely convulsions, thyroid storms, acute psychosis, arrhythmias, and acute myocardial infarction may occur. Laboratory workup usually reveals elevated serum total T4 and T3, suppressed serum TSH, and elevated Free T4 and Free T3.</p>
        <p>Employ the following treatment approach in acute levothyroxine overdose.&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Administer activated charcoal to prevent the absorption of levothyroxine.</p>
          </list-item>
          <list-item>
            <p>Cholestyramine binds thyroxine and enhances its elimination. The dose used is 4 grams orally every 8 hours.<xref ref-type="bibr" rid="article-24233.r30">[30]</xref></p>
          </list-item>
          <list-item>
            <p>Beta-blockers are beneficial to alleviate the metabolic effects of thyroid hormone, mainly on the cardiac system (controlling tachycardia, preventing arrhythmias). Propranolol also blocks the peripheral conversion of T4 to T3.</p>
          </list-item>
          <list-item>
            <p>Glucocorticoids such as (Dexamethasone 4 mg orally) can reduce the conversion of LT4 to T3, the active hormone.</p>
          </list-item>
          <list-item>
            <p>Propylthiouracil can be used to prevent the conversion of T4 to T3.</p>
          </list-item>
          <list-item>
            <p>Hemodialysis is utilized in severe cases, but it is of limited benefit since T3 and T4 are primarily protein-bound.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Hemoperfusion utilizing activated charcoal is a complex but efficient procedure for reducing thyroxine levels. Therefore, reserve it for adult patients with severe intoxication.<xref ref-type="bibr" rid="article-24233.r31">[31]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>The severe cases of intoxication leading to a thyroid storm require treatment in a MICU.<xref ref-type="bibr" rid="article-24233.r32">[32]</xref></p>
          </list-item>
        </list>
        <p>In summary, it is essential to note that there is no antidote to treat levothyroxine overdose. Treatment options include gastric lavage, activated charcoal, cholestyramine, glucocorticoids, beta-blockers, propylthiouracil, and supportive measures.<xref ref-type="bibr" rid="article-24233.r33">[33]</xref></p>
      </sec>
      <sec id="article-24233.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Upon first prescribing levothyroxine, medication adjustment should occur every 6 to 8 weeks until the patient reaches a steady state.&#x000a0;Clinicians should also evaluate the response to&#x000a0;levothyroxine by using a validated questionnaire, such as&#x000a0;thyroid-related quality of life (ThyPRO) and the underactive thyroid treatment satisfaction questionnaire (ThySRQ).<xref ref-type="bibr" rid="article-24233.r34">[34]</xref><xref ref-type="bibr" rid="article-24233.r35">[35]</xref>&#x000a0;If the patient has symptoms of hyperthyroidism, advise the patient to contact the clinician to determine if these are side effects of the medication. A clinician should then order TSH and free T4 levels immediately. If the free T4 comes back elevated, the clinician should decrease the dose of levothyroxine to prevent cardiac complications and other symptoms of hyperthyroidism. Finally, clinicians should refer the patient to an endocrinologist if hypothyroidism is due to central causes. In all the scenarios mentioned above, pharmacists should ensure proper dosing and report to the clinician if there is any potential drug-drug interaction or if supplies may dictate a change to a different formulation.&#x000a0;</p>
        <p>In an acute overdose of levothyroxine, emergency department physician and triage nurses stabilize the patient, focusing on maintaining a patent airway, breathing, and circulation. Critical care physicians play an essential role in managing thyroid storms. In the case of extreme overdose where hemoperfusion or hemodialysis is planned, a nephrologist referral is required.<xref ref-type="bibr" rid="article-24233.r31">[31]</xref>&#x000a0;In such cases, nursing will play a crucial role in monitoring the patient, administering medication, and reporting any patient status changes to the clinician. As described above, multiple healthcare professionals take care of the patient prescribed levothyroxine for various indications. An interprofessional team-based approach involving clinicians (MDs, DOs, NPs, PAs), specialists, nurses, pharmacists, and other healthcare providers achieves maximum efficacy. It minimizes the adverse drug reactions associated with levothyroxine therapy which translates to improved patient outcomes. [Level 5]</p>
      </sec>
      <sec id="article-24233.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=24233&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=24233">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/24233/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=24233">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-24233.s11">
        <title>References</title>
        <ref id="article-24233.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cooper</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Halpern</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Wood</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Levin</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Ridgway</surname>
                <given-names>EC</given-names>
              </name>
            </person-group>
            <article-title>L-Thyroxine therapy in subclinical hypothyroidism. A double-blind, placebo-controlled trial.</article-title>
            <source>Ann Intern Med</source>
            <year>1984</year>
            <month>Jul</month>
            <volume>101</volume>
            <issue>1</issue>
            <fpage>18</fpage>
            <page-range>18-24</page-range>
            <pub-id pub-id-type="pmid">6428290</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24233.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chaker</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bianco</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Jonklaas</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Peeters</surname>
                <given-names>RP</given-names>
              </name>
            </person-group>
            <article-title>Hypothyroidism.</article-title>
            <source>Lancet</source>
            <year>2017</year>
            <month>Sep</month>
            <day>23</day>
            <volume>390</volume>
            <issue>10101</issue>
            <fpage>1550</fpage>
            <page-range>1550-1562</page-range>
            <pub-id pub-id-type="pmid">28336049</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24233.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Haugen</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>Alexander</surname>
                <given-names>EK</given-names>
              </name>
              <name>
                <surname>Bible</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Doherty</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Mandel</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Nikiforov</surname>
                <given-names>YE</given-names>
              </name>
              <name>
                <surname>Pacini</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Randolph</surname>
                <given-names>GW</given-names>
              </name>
              <name>
                <surname>Sawka</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Schlumberger</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Schuff</surname>
                <given-names>KG</given-names>
              </name>
              <name>
                <surname>Sherman</surname>
                <given-names>SI</given-names>
              </name>
              <name>
                <surname>Sosa</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Steward</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Tuttle</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Wartofsky</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.</article-title>
            <source>Thyroid</source>
            <year>2016</year>
            <month>Jan</month>
            <volume>26</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-133</page-range>
            <pub-id pub-id-type="pmid">26462967</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24233.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ono</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ono</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yasunaga</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Matsui</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Fushimi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tanaka</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Clinical characteristics and outcomes of myxedema coma: Analysis of a national inpatient database in Japan.</article-title>
            <source>J Epidemiol</source>
            <year>2017</year>
            <month>Mar</month>
            <volume>27</volume>
            <issue>3</issue>
            <fpage>117</fpage>
            <page-range>117-122</page-range>
            <pub-id pub-id-type="pmid">28142035</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24233.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Salim</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vassiliu</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Velmahos</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Sava</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Murray</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Belzberg</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Asensio</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Demetriades</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>The role of thyroid hormone administration in potential organ donors.</article-title>
            <source>Arch Surg</source>
            <year>2001</year>
            <month>Dec</month>
            <volume>136</volume>
            <issue>12</issue>
            <fpage>1377</fpage>
            <page-range>1377-80</page-range>
            <pub-id pub-id-type="pmid">11735863</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24233.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Calissendorff</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Falhammar</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>To Treat or Not to Treat Subclinical Hypothyroidism, What Is the Evidence?</article-title>
            <source>Medicina (Kaunas)</source>
            <year>2020</year>
            <month>Jan</month>
            <day>19</day>
            <volume>56</volume>
            <issue>1</issue>
            <pub-id pub-id-type="pmid">31963883</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24233.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khandelwal</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Tandon</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Overt and subclinical hypothyroidism: who to treat and how.</article-title>
            <source>Drugs</source>
            <year>2012</year>
            <month>Jan</month>
            <day>01</day>
            <volume>72</volume>
            <issue>1</issue>
            <fpage>17</fpage>
            <page-range>17-33</page-range>
            <pub-id pub-id-type="pmid">22191793</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24233.r8">
          <label>8</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Rousset</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Dupuy</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Miot</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Dumont</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <chapter-title>Chapter 2 Thyroid Hormone Synthesis And Secretion</chapter-title>
            <person-group person-group-type="editor">
              <name>
                <surname>Feingold</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Anawalt</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Blackman</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Boyce</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chrousos</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Corpas</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>de Herder</surname>
                <given-names>WW</given-names>
              </name>
              <name>
                <surname>Dhatariya</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Dungan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hofland</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kalra</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kaltsas</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kapoor</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Koch</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kopp</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Korbonits</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kovacs</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Kuohung</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Laferr&#x000e8;re</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>McGee</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>McLachlan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>New</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Purnell</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sahay</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Singer</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Sperling</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Stratakis</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Trence</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>DP</given-names>
              </name>
            </person-group>
            <source>Endotext [Internet]</source>
            <publisher-name>MDText.com, Inc.</publisher-name>
            <publisher-loc>South Dartmouth (MA)</publisher-loc>
            <year>2015</year>
            <month>9</month>
            <day>2</day>
            <pub-id pub-id-type="pmid">25905405</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24233.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Anyetei-Anum</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Roggero</surname>
                <given-names>VR</given-names>
              </name>
              <name>
                <surname>Allison</surname>
                <given-names>LA</given-names>
              </name>
            </person-group>
            <article-title>Thyroid hormone receptor localization in target tissues.</article-title>
            <source>J Endocrinol</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>237</volume>
            <issue>1</issue>
            <fpage>R19</fpage>
            <page-range>R19-R34</page-range>
            <pub-id pub-id-type="pmid">29440347</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24233.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fish</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Schwartz</surname>
                <given-names>HL</given-names>
              </name>
              <name>
                <surname>Cavanaugh</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Steffes</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>Bantle</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Oppenheimer</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>Replacement dose, metabolism, and bioavailability of levothyroxine in the treatment of hypothyroidism. Role of triiodothyronine in pituitary feedback in humans.</article-title>
            <source>N Engl J Med</source>
            <year>1987</year>
            <month>Mar</month>
            <day>26</day>
            <volume>316</volume>
            <issue>13</issue>
            <fpage>764</fpage>
            <page-range>764-70</page-range>
            <pub-id pub-id-type="pmid">3821822</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24233.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ianiro</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Mangiola</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Di Rienzo</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Bibb&#x000f2;</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Franceschi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Greco</surname>
                <given-names>AV</given-names>
              </name>
              <name>
                <surname>Gasbarrini</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Levothyroxine absorption in health and disease, and new therapeutic perspectives.</article-title>
            <source>Eur Rev Med Pharmacol Sci</source>
            <year>2014</year>
            <volume>18</volume>
            <issue>4</issue>
            <fpage>451</fpage>
            <page-range>451-6</page-range>
            <pub-id pub-id-type="pmid">24610609</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24233.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kashiwagura</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Uchida</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tanaka</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Watanabe</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Masuzawa</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sasaki</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Namiki</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Clinical efficacy and pharmacokinetics of levothyroxine suppository in patients with hypothyroidism.</article-title>
            <source>Biol Pharm Bull</source>
            <year>2014</year>
            <volume>37</volume>
            <issue>4</issue>
            <fpage>666</fpage>
            <page-range>666-70</page-range>
            <pub-id pub-id-type="pmid">24694613</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24233.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Garber</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Cobin</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Gharib</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hennessey</surname>
                <given-names>JV</given-names>
              </name>
              <name>
                <surname>Klein</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Mechanick</surname>
                <given-names>JI</given-names>
              </name>
              <name>
                <surname>Pessah-Pollack</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Singer</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Woeber</surname>
                <given-names>KA</given-names>
              </name>
              <collab>American Association of Clinical Endocrinologists and American Thyroid Association Taskforce on Hypothyroidism in Adults</collab>
            </person-group>
            <article-title>Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association.</article-title>
            <source>Endocr Pract</source>
            <year>2012</year>
            <season>Nov-Dec</season>
            <volume>18</volume>
            <issue>6</issue>
            <fpage>988</fpage>
            <page-range>988-1028</page-range>
            <pub-id pub-id-type="pmid">23246686</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24233.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Clarke</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kabadi</surname>
                <given-names>UM</given-names>
              </name>
            </person-group>
            <article-title>Optimizing treatment of hypothyroidism.</article-title>
            <source>Treat Endocrinol</source>
            <year>2004</year>
            <volume>3</volume>
            <issue>4</issue>
            <fpage>217</fpage>
            <page-range>217-21</page-range>
            <pub-id pub-id-type="pmid">16026104</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24233.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jonklaas</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bianco</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Bauer</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Burman</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Cappola</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Celi</surname>
                <given-names>FS</given-names>
              </name>
              <name>
                <surname>Cooper</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>BW</given-names>
              </name>
              <name>
                <surname>Peeters</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Rosenthal</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Sawka</surname>
                <given-names>AM</given-names>
              </name>
              <collab>American Thyroid Association Task Force on Thyroid Hormone Replacement</collab>
            </person-group>
            <article-title>Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacement.</article-title>
            <source>Thyroid</source>
            <year>2014</year>
            <month>Dec</month>
            <volume>24</volume>
            <issue>12</issue>
            <fpage>1670</fpage>
            <page-range>1670-751</page-range>
            <pub-id pub-id-type="pmid">25266247</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24233.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nath</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Ilias Basha</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Moazami</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ewald</surname>
                <given-names>GA</given-names>
              </name>
            </person-group>
            <article-title>Increased recovery of thoracic organs after hormonal resuscitation therapy.</article-title>
            <source>J Heart Lung Transplant</source>
            <year>2010</year>
            <month>May</month>
            <volume>29</volume>
            <issue>5</issue>
            <fpage>594</fpage>
            <page-range>594-6</page-range>
            <pub-id pub-id-type="pmid">20207554</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24233.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alexander</surname>
                <given-names>EK</given-names>
              </name>
              <name>
                <surname>Marqusee</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Lawrence</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jarolim</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Fischer</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Larsen</surname>
                <given-names>PR</given-names>
              </name>
            </person-group>
            <article-title>Timing and magnitude of increases in levothyroxine requirements during pregnancy in women with hypothyroidism.</article-title>
            <source>N Engl J Med</source>
            <year>2004</year>
            <month>Jul</month>
            <day>15</day>
            <volume>351</volume>
            <issue>3</issue>
            <fpage>241</fpage>
            <page-range>241-9</page-range>
            <pub-id pub-id-type="pmid">15254282</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24233.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alexander</surname>
                <given-names>EK</given-names>
              </name>
              <name>
                <surname>Pearce</surname>
                <given-names>EN</given-names>
              </name>
              <name>
                <surname>Brent</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Dosiou</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Grobman</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Laurberg</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lazarus</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Mandel</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Peeters</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Sullivan</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum.</article-title>
            <source>Thyroid</source>
            <year>2017</year>
            <month>Mar</month>
            <volume>27</volume>
            <issue>3</issue>
            <fpage>315</fpage>
            <page-range>315-389</page-range>
            <pub-id pub-id-type="pmid">28056690</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24233.r19">
          <label>19</label>
          <element-citation publication-type="book">
            <chapter-title>Levothyroxine</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2023</year>
            <month>9</month>
            <day>15</day>
            <pub-id pub-id-type="pmid">30000062</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24233.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Choi</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>WY</given-names>
              </name>
              <name>
                <surname>Kang</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Koh</surname>
                <given-names>YI</given-names>
              </name>
              <name>
                <surname>Bae</surname>
                <given-names>EH</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>SW</given-names>
              </name>
            </person-group>
            <article-title>Drug rash induced by levothyroxine tablets.</article-title>
            <source>Thyroid</source>
            <year>2012</year>
            <month>Oct</month>
            <volume>22</volume>
            <issue>10</issue>
            <fpage>1090</fpage>
            <pub-id pub-id-type="pmid">22962862</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24233.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gong</surname>
                <given-names>IY</given-names>
              </name>
              <name>
                <surname>Atzema</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Lega</surname>
                <given-names>IC</given-names>
              </name>
              <name>
                <surname>Austin</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Na</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Rochon</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Lipscombe</surname>
                <given-names>LL</given-names>
              </name>
            </person-group>
            <article-title>Levothyroxine dose and risk of atrial fibrillation: A nested case-control study.</article-title>
            <source>Am Heart J</source>
            <year>2021</year>
            <month>Feb</month>
            <volume>232</volume>
            <fpage>47</fpage>
            <page-range>47-56</page-range>
            <pub-id pub-id-type="pmid">33022231</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24233.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bousquet</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lagier</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Lillo-Le Lou&#x000eb;t</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Le Beller</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Venot</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jaulent</surname>
                <given-names>MC</given-names>
              </name>
            </person-group>
            <article-title>Appraisal of the MedDRA conceptual structure for describing and grouping adverse drug reactions.</article-title>
            <source>Drug Saf</source>
            <year>2005</year>
            <volume>28</volume>
            <issue>1</issue>
            <fpage>19</fpage>
            <page-range>19-34</page-range>
            <pub-id pub-id-type="pmid">15649103</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24233.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mustafa</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ozg&#x000fc;l</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Zehra</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>H&#x000fc;lya</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Transient ST-segment elevation due to iatrogenic hyperthyroidism in a patient with normal coronary arteries.</article-title>
            <source>Intern Med</source>
            <year>2011</year>
            <volume>50</volume>
            <issue>15</issue>
            <fpage>1595</fpage>
            <page-range>1595-7</page-range>
            <pub-id pub-id-type="pmid">21804288</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24233.r24">
          <label>24</label>
          <element-citation publication-type="book">
            <chapter-title>Thyroid Hormone</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2019</year>
            <month>4</month>
            <day>15</day>
            <pub-id pub-id-type="pmid">31643816</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24233.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Colucci</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Yue</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Ducharme</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Benvenga</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>A Review of the Pharmacokinetics of Levothyroxine for the Treatment of Hypothyroidism.</article-title>
            <source>Eur Endocrinol</source>
            <year>2013</year>
            <month>Mar</month>
            <volume>9</volume>
            <issue>1</issue>
            <fpage>40</fpage>
            <page-range>40-47</page-range>
            <pub-id pub-id-type="pmid">30349610</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24233.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brahmer</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Lacchetti</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Schneider</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Atkins</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Brassil</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Caterino</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Chau</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Ernstoff</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Gardner</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Ginex</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hallmeyer</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Holter Chakrabarty</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Leighl</surname>
                <given-names>NB</given-names>
              </name>
              <name>
                <surname>Mammen</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>McDermott</surname>
                <given-names>DF</given-names>
              </name>
              <name>
                <surname>Naing</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nastoupil</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Phillips</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Porter</surname>
                <given-names>LD</given-names>
              </name>
              <name>
                <surname>Puzanov</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Reichner</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Santomasso</surname>
                <given-names>BD</given-names>
              </name>
              <name>
                <surname>Seigel</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Spira</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Suarez-Almazor</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Weber</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Wolchok</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>JA</given-names>
              </name>
              <collab>National Comprehensive Cancer Network</collab>
            </person-group>
            <article-title>Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.</article-title>
            <source>J Clin Oncol</source>
            <year>2018</year>
            <month>Jun</month>
            <day>10</day>
            <volume>36</volume>
            <issue>17</issue>
            <fpage>1714</fpage>
            <page-range>1714-1768</page-range>
            <pub-id pub-id-type="pmid">29442540</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24233.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Persani</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Clinical review: Central hypothyroidism: pathogenic, diagnostic, and therapeutic challenges.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2012</year>
            <month>Sep</month>
            <volume>97</volume>
            <issue>9</issue>
            <fpage>3068</fpage>
            <page-range>3068-78</page-range>
            <pub-id pub-id-type="pmid">22851492</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24233.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wartofsky</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Levothyroxine: therapeutic use and regulatory issues related to bioequivalence.</article-title>
            <source>Expert Opin Pharmacother</source>
            <year>2002</year>
            <month>Jun</month>
            <volume>3</volume>
            <issue>6</issue>
            <fpage>727</fpage>
            <page-range>727-32</page-range>
            <pub-id pub-id-type="pmid">12036412</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24233.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hauge</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Breitschaft</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hartoft-Nielsen</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Jensen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>B&#x000e6;kdal</surname>
                <given-names>TA</given-names>
              </name>
            </person-group>
            <article-title>Effect of oral semaglutide on the pharmacokinetics of thyroxine after dosing of levothyroxine and the influence of co-administered tablets on the pharmacokinetics of oral semaglutide in healthy subjects: an open-label, one-sequence crossover, single-center, multiple-dose, two-part trial.</article-title>
            <source>Expert Opin Drug Metab Toxicol</source>
            <year>2021</year>
            <month>Sep</month>
            <volume>17</volume>
            <issue>9</issue>
            <fpage>1139</fpage>
            <page-range>1139-1148</page-range>
            <pub-id pub-id-type="pmid">34289755</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24233.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>de Luis</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Due&#x000f1;as</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Abad</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Cuellar</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Aller</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Light symptoms following a high-dose intentional L-thyroxine ingestion treated with cholestyramine.</article-title>
            <source>Horm Res</source>
            <year>2002</year>
            <volume>57</volume>
            <issue>1-2</issue>
            <fpage>61</fpage>
            <page-range>61-3</page-range>
            <pub-id pub-id-type="pmid">12006723</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24233.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kreisner</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Lutzky</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gross</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>Charcoal hemoperfusion in the treatment of levothyroxine intoxication.</article-title>
            <source>Thyroid</source>
            <year>2010</year>
            <month>Feb</month>
            <volume>20</volume>
            <issue>2</issue>
            <fpage>209</fpage>
            <page-range>209-12</page-range>
            <pub-id pub-id-type="pmid">20151829</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24233.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chiha</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Samarasinghe</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kabaker</surname>
                <given-names>AS</given-names>
              </name>
            </person-group>
            <article-title>Thyroid storm: an updated review.</article-title>
            <source>J Intensive Care Med</source>
            <year>2015</year>
            <month>Mar</month>
            <volume>30</volume>
            <issue>3</issue>
            <fpage>131</fpage>
            <page-range>131-40</page-range>
            <pub-id pub-id-type="pmid">23920160</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24233.r33">
          <label>33</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Medeiros-Neto</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <chapter-title>Thyroxine Poisoning</chapter-title>
            <person-group person-group-type="editor">
              <name>
                <surname>Feingold</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Anawalt</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Blackman</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Boyce</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chrousos</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Corpas</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>de Herder</surname>
                <given-names>WW</given-names>
              </name>
              <name>
                <surname>Dhatariya</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Dungan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hofland</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kalra</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kaltsas</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kapoor</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Koch</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kopp</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Korbonits</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kovacs</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Kuohung</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Laferr&#x000e8;re</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>McGee</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>McLachlan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>New</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Purnell</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sahay</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Singer</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Sperling</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Stratakis</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Trence</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>DP</given-names>
              </name>
            </person-group>
            <source>Endotext [Internet]</source>
            <publisher-name>MDText.com, Inc.</publisher-name>
            <publisher-loc>South Dartmouth (MA)</publisher-loc>
            <year>2018</year>
            <month>7</month>
            <day>17</day>
            <pub-id pub-id-type="pmid">25905265</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24233.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Watt</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Cramon</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Heged&#x000fc;s</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bjorner</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Bonnema</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Rasmussen</surname>
                <given-names>&#x000c5;K</given-names>
              </name>
              <name>
                <surname>Feldt-Rasmussen</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Groenvold</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>The thyroid-related quality of life measure ThyPRO has good responsiveness and ability to detect relevant treatment effects.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2014</year>
            <month>Oct</month>
            <volume>99</volume>
            <issue>10</issue>
            <fpage>3708</fpage>
            <page-range>3708-17</page-range>
            <pub-id pub-id-type="pmid">25004246</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24233.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Quinque</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Villringer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kratzsch</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Karger</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Patient-reported outcomes in adequately treated hypothyroidism - insights from the German versions of ThyDQoL, ThySRQ and ThyTSQ.</article-title>
            <source>Health Qual Life Outcomes</source>
            <year>2013</year>
            <month>Apr</month>
            <day>23</day>
            <volume>11</volume>
            <fpage>68</fpage>
            <pub-id pub-id-type="pmid">23618009</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
